Cargando…
Real World Evidence on the Effectiveness of Nusinersen within the National Program to Treat Spinal Muscular Atrophy in Poland
Background: Spinal muscular atrophy (SMA) is a debilitating neuromuscular disease resulting in children’s mortality and disability. Nusinersen is available to all SMA patients in Poland since 2019. Aim: To compare mortality or disease progression to mechanical ventilation in two patient cohorts befo...
Autores principales: | Krupa, Dominika, Czech, Marcin, Chudzyńska, Ewa, Koń, Beata, Kostera-Pruszczyk, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218344/ https://www.ncbi.nlm.nih.gov/pubmed/37239800 http://dx.doi.org/10.3390/healthcare11101515 |
Ejemplares similares
-
Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience
por: Łusakowska, Anna, et al.
Publicado: (2023) -
Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018) -
Ultra-low radiation dose protocol for CT-guided intrathecal nusinersen injections for patients with spinal muscular atrophy and severe scoliosis
por: Rosiak, Grzegorz, et al.
Publicado: (2021) -
Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021) -
Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)